GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B1350 Timolol MaleateSummary: Non-selective, beta-adrenergic receptor antagonist -
B2244 Atomoxetine HClSummary: Noradrenalin re-uptake inhibitor -
B1001 Loxapine1 CitationTarget: 5-HT2 ReceptorsSummary: 5-HT receptor antagonist -
B1203 Iloperidone hydrochlorideSummary: D(2)/5-HT(2) receptor antagonistis -
B1071 Azilsartan medoxomil monopotassiumSummary: Angiotensin II receptor type 1 antagonist -
B1919 Cortisone acetateSummary: Glucocorticoid receptor agonist -
B2012 PrednisoloneSummary: synthetic glucocorticoid -
B2068 ZafirlukastTarget: Leukotriene and Related ReceptorsSummary: oral leukotriene receptor antagonist -
B1072 LosartanSummary: Angiotensin II receptor antagonist -
B1179 S1RASummary: σ1R antagonist

